RxDoctor Payments Data

Kenneth Chang, MD

Internal Medicine · San Francisco, CANPI 1609832724

Payments from drug & device makers

$3,062in general payments, 2019–2025

Across 85 payments — averaging $36.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Intuitive Surgical$740
  • Medtronic$380
  • Novo Nordisk$202
  • Genentech USA, Inc.$138
  • Gilead$89
  • plus $183 from 4 others

What the payments were for

  • Travel & lodging$1,07435%
  • Food & beverage$1,96464%
  • Education$60%
  • Gifts$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson58$1,330
Intuitive Surgical3$740
Medtronic3$380
Novo Nordisk9$202
Genentech USA, Inc.1$138
Gilead5$89
Pfizer1$86
AbbVie3$68
Ascend Therapeutics US, LLC1$18
Creo Medical Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,062 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$235,190
Medicare patients
422
Services billed
2,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate277$341,086
EliquisApixaban234$302,346
JardianceEmpagliflozin204$282,995
CreonLipase/Protease/Amylase33$60,664
FarxigaDapagliflozin Propanediol43$53,391
XareltoRivaroxaban40$48,858
TradjentaLinagliptin44$34,863
VemlidyTenofovir Alafenamide12$28,276
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$23,882
OzempicSemaglutide25$23,242
JanumetSitagliptin Phos/Metformin Hcl18$23,140
Memantine Hcl ErMemantine Hcl59$15,522
EntrestoSacubitril/Valsartan12$15,022
Combivent RespimatIpratropium/Albuterol Sulfate16$13,086
Atorvastatin Calcium1,910$13,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$302,346234 claims
AbbVieCreon$68$60,66433 claims
Johnson & JohnsonXarelto$1,330$48,85840 claims
GileadVemlidy$89$28,27612 claims
Novo NordiskOzempic$202$23,24225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →